Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.
If you were prescribed this medicine, other products containing Insulin aspart may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.
for
Trurapi is used to reduce the high blood sugar level in adults, adolescents and children aged 1 year and above with diabetes mellitus (diabetes). Diabetes is a disease where your body does not produce enough insulin to control the level of your blood sugar. Treatment with insulin aspart helps to prevent complications from your diabetes. Insulin aspart will start to lower your blood sugar 10-20 minutes after you inject it, a maximum effect occurs between 1 and 3 hours after the injection and the effect lasts for 3-5 hours. Due to this short action insulin aspart should normally be taken in combination with intermediate‐acting or long‐acting insulin preparations.
e Trurapi Do not use Trurapi
Some conditions and activities can affect your need for insulin. Consult your doctor:
Ask your doctor, nurse or pharmacist for advice before using this medicine while pregnant or breast-feeding. Driving and using machines Please ask your doctor whether you can drive a car or use a machine:
Your blood sugar level may fall (hypoglycaemia) if you take:
3. How to use Trurapi
Pioglitazone (tablets used for the treatment of type 2 diabetes) Some patients with long-standing type 2 diabetes and heart disease or previous stroke who were treated with pioglitazone and insulin experienced the development of heart failure. Inform your doctor as soon as possible if you experience signs of heart failure such as unusual shortness of breath or rapid increase in weight or localised swelling (oedema). If you have taken any of the medicines listed here, tell your doctor, nurse or pharmacist. Insulin aspart and alcohol If you drink alcohol, your need for insulin may change as your blood sugar level may either rise or fall. Careful monitoring is recommended.
4. Possible side effects
Uncommon (may affect up to 1 in 100 people)
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Signs of allergy: Local allergic reactions (pain, redness, hives, inflammation, bruising, swelling and itching) at the injection site may occur. These usually disappear after a few weeks of using your insulin. If they do not disappear, or if they spread throughout your body, talk to your doctor immediately (see also "Serious allergic reactions" above).
If you stop using your insulin Do not stop using your insulin without speaking with a doctor, who will tell you what needs to be done. This could lead to very high blood sugar (severe hyperglycaemia) and ketoacidosis (see "Effects from diabetes" in section 4).
Trurapi contains sodium This medicine contains less than 1 mmol (23 mg) sodium per dose, that is to say essentially "sodiumfree".
Beta-blockers (used to treat high blood pressure) may weaken or suppress entirely the first warning symptoms which help you to recognise low blood sugar.
Keep this medicine out of the sight and reach of children.
If you have any further questions on the use of this medicine, ask your doctor, nurse or pharmacist.
Skin changes at the injection site: If you inject insulin too often at the same place, the fatty tissue under the skin at the injection site may shrink (lipoatrophy) or thicken (lipohypertrophy) (may affect up to 1 in 100 people). Lumps under the skin may also be caused by build-up of a protein called amyloid (cutaneous amyloidosis; how often this occurs is not known). The insulin may not work very well if you inject into a lumpy area. Change the injection site with each injection to help prevent these skin changes. If you notice your skin pitting or thickening at the injection site, tell your doctor or nurse. These reactions can become more severe, or they may change the absorption of your insulin, if you inject in such a site.
There are no restrictions on treatment with insulin aspart during breast-feeding.
Trurapi has a rapid onset of effect therefore if hypoglycaemia occurs, you may experience it earlier after an injection when compared to soluble human insulin.
Octreotide and lanreotide (used for treatment of acromegaly, a rare hormonal disorder that usually occurs in middle-aged adults, caused by the pituitary gland producing excess growth hormone) may either increase or decrease your blood sugar level.
5. How to store Trurapi
If you use more insulin than you should If you use too much insulin your blood sugar gets too low (hypoglycaemia) (see "Summary of serious and very common side effects" in section 4).
Other medicines and Trurapi Tell your doctor, nurse or pharmacist if you are taking, have recently taken or might take any other medicines. Some medicines affect your blood sugar level and this may mean that your insulin dose has to change. Listed below are the most common medicines which may affect your insulin treatment.
Your blood sugar level may rise (hyperglycaemia) if you take:
Other side effects
Pregnancy and breast-feeding If you are pregnant, think you may be pregnant or are planning to have a baby, ask your doctor for advice before using this medicine. Insulin aspart can be used during pregnancy. Your insulin dose may need to be changed during pregnancy and after delivery. Careful control of your diabetes, particularly prevention of hypoglycaemia, is important for the health of your baby.
Dose and when to use your insulin Always use your insulin and adjust your dose exactly as your doctor has told you. Check with your doctor, nurse or pharmacist if you are not sure. Insulin aspart is generally used immediately before a meal. Eat a meal or snack within 10 minutes of the injection to avoid low blood sugar. When necessary, insulin aspart can be given soon after a meal (see "How and where to inject" below for information). Do not change your insulin unless your doctor tells you to. If your doctor has switched you from one type or brand of insulin to another, your dose may have to be adjusted by your doctor. Use in children and adolescents Insulin aspart can be used in adolescents and children aged 1 year and above instead of soluble human insulin when a rapid onset of effect is preferred. For example, when it is difficult to dose the child in relation to meals. Use in special patient groups If you have reduced kidney or liver function, or if you are above 65 years of age, you need to check your blood sugar more regularly and discuss changes in your insulin dose with your doctor.
and where to inject Trurapi is for injection under the skin (subcutaneously). You must never inject yourself directly into a vein (intravenously) or muscle (intramuscularly). Trurapi is only suitable for injecting under the skin. Speak to your doctor if you need to inject your insulin by another method. With each injection, change the injection site within the particular area of skin that you use. This may reduce the risk of developing lumps or skin pitting (see section 4 "Possible side effects"). The best places to give yourself an injection are: the front of your waist (abdomen), the upper arm or the front of your thighs. The insulin will work more quickly if you inject into the front of your waist (abdomen). You should always measure your blood sugar regularly. How to handle Trurapi pre‐filled pen Trurapi is available in a pre-filled disposable pen (called SoloStar) containing insulin aspart. Each SoloStar pen delivers 1-80 units in increments of 1 unit. Read carefully the instructions for use included in this package leaflet. You must use the pen as described in the Instructions for Use.
If you forget to use your insulin If you forget to use your insulin your blood sugar may get too high (hyperglycaemia) (see "Effects from diabetes" in section 4).
Summary of serious and very common side effects Low blood sugar (hypoglycaemia) is a very common side effect. It may affect more than 1 in 10 people. Low blood sugar may occur if you:
Always ensure you use the correct pen before you inject your insulin.
Legende / Legend SAP-Nr. / Plant PM code: Sprachvariante / Country code: Version: Datum / Date: DMC-Inhalt / DMC content:
954212 028 2 09.02.2026 DR07 <MAT>954212
Abmessungen / Dimensions: Schriftgröße / Font size: Zeilenabstand / Line spacing: Seite / Page:
594 × 420 mm 10 Pt 11 Pt 1/2
Druckbare Farben / Printing colours
Technische Information / Technical information
Black
Kontur / Outline
Vision problems: When you first start your insulin treatment, it may disturb your vision, but the disturbance is usually temporary. Swollen joints: When you start using insulin, water retention may cause swelling around your ankles and other joints. Normally this soon disappears. If not, talk to your doctor. Diabetic retinopathy (an eye disease related to diabetes which can lead to loss of vision): If you have diabetic retinopathy and your blood sugar level improves very fast, the retinopathy may get worse. Ask your doctor about this. Rare (may affect up to 1 in 1,000 people) Painful neuropathy (pain due to nerve damage): If your blood sugar level improves very fast, you may get nerve related pain. This is called acute painful neuropathy and is usually transient. Reporting of side effects If you get any side effects, talk to your doctor, nurse or pharmacist. This includes any
not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine. Effects from diabetes High blood sugar (hyperglycaemia)
Do not use this medicine after the expiry date which is stated on the label and carton. The expiry date refers to the last day of that month. Before the first use store your Trurapi in a refrigerator (2°C – 8°C). Do not freeze. Keep the pre-filled pen in the outer carton in order to protect from light. Keep your Trurapi pre‐filled pen in use at room temperature (below 30°C) for a maximum of 4 weeks. Do not keep the pre‐filled pen that you are using in the fridge. The pre‐filled pen should not be stored with the needle attached. Always keep the cap on the pre‐filled pen when you are not using it in order to protect from light. Do not use Trurapi pre-filled pen if the solution is coloured or it has solid pieces in it. You must use it only if it looks like water. Check this each time you inject yourself. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.
and care for your pen
Handling needles
If you see air bubbles
Units of insulin in your pen
If you find it hard to press the button in:
Legende / Legend SAP-Nr. / Plant PM code: Sprachvariante / Country code: Version: Datum / Date:
954212 028 2 09.02.2026 DR07
Abmessungen / Dimensions: Schriftgröße / Font size: Zeilenabstand / Line spacing: Seite / Page:
594 × 420 mm 10 Pt 11 Pt 2/2
Druckbare Farben / Printing colours
Technische Information / Technical information
Cyan Magenta Yellow Black
Kontur / Outline
What Trurapi contains
High blood sugar may occur if you:
Manufacturer Sanofi-Aventis Deutschland GmbH, D-65926 Frankfurt am Main, Germany.
Warning signs of high blood sugar: The warning signs appear gradually. They include: increased urination; feeling thirsty; losing your appetite; feeling sick (nausea or vomiting); feeling drowsy or tired; flushed; dry skin; dry mouth and a fruity (acetone) smell of the breath.
This leaflet was last revised in February 2026
What to do if you experience high blood sugar
This leaflet does not contain all the information about your medicine. If you have any questions or are not sure about anything, ask your doctor or pharmacist
<MAT>954212
Trurapi is a modern insulin (insulin analogue) with a rapid-acting effect. Modern insulin products are improved versions of human insulin.
Skin changes at the injection site The injection site should be rotated to prevent skin changes such as lumps under the skin. The insulin may not work very well if you inject into a lumpy area (see "How to use Trurapi"). Contact your doctor if you are currently injecting into a lumpy area before you start injecting in a different area. Your doctor may tell you to check your blood sugar more closely, and to adjust your insulin or your other antidiabetic medications dose.
Trurapi solution for injection in pre-filled pen (SoloStar) INSTRUCTIONS FOR USE Important information
✗ Never share your pen – it is only for you. ✗ Never use your pen if it is damaged or if you are not sure that it is working
✓ Take a new pen out of the fridge at least 1 hour
✓ Always use a new sterile needle for each injection.
✓ Always do a safety test before each injection – this is
✗
✓
✓ ✓
Rubber seal Insulin scale
to: check your pen and the needle are working properly. make sure that you get the correct insulin dose.
Select 2 units by turning the dose selector until the dose pointer is at the 2 mark.
Never select a dose or press the injection button without a needle attached. This may damage your pen.
Make sure a needle is attached and the dose is set to '0'.
STEP 5: Inject your dose
✗
If you find it hard to press the injection button in, do not force it as this may break your pen. See the section below for help.
Choose a place to inject as shown in the picture
220
260
140
180
20
60
100
220
260
100
140
180
20
60
Stomach
60
100
140
180
Turn the dose selector until the dose pointer lines up with your dose.
Press the injection button all the way in.
Push the needle into your skin as shown by your doctor, pharmacist or nurse.
20 60 100 140 180 220
02
06
001
041
20 60
081
260
022
220
062
✓ Take care when handling needles – this is to prevent ✗
needle injury and cross-infection. Never put the inner needle cap back on.
Put the outer needle cap back on the needle, and use it to unscrew the needle from the pen.
260
100
140
180
20
60
Place your thumb on the injection button. Then press all the way in and hold.
260
180
220
100
140
20
60
Pull off the outer needle cap. Keep this for later.
Buttocks
Thighs
20
20
60
100
140
180
220
260
20
60
100
140
180
220
260
220
260
Keep the needle straight and screw it onto the pen until fixed. Do not overtighten.
Check that the insulin is clear.
Injection button
Plunger*
STEP 6: Remove the needle
Upper arms
Pull off the pen cap.
260
STEP 4: Select the dose
Take a new needle and peel off the protective seal.
Dose pointer
STEP 3: Do a safety test
Check the name and expiry date on the label of your pen.
Dose window
Dose selector Pen cap
STEP 2: Attach a new needle This helps stop blocked needles, contamination and infection. Only use needles that are compatible for use with Trurapi
Insulin name
Cartridge holder
180
220
If you have any questions about your pen or about diabetes, ask your doctor, pharmacist or nurse or call the Sanofi number on the front of this leaflet.
100
STEP 1: Check your pen before you inject. Cold insulin is more painful to inject.
Get to know your pen
140
Extra items you will need:
20
properly. ✓ Always perform a safety test. ✓ Always carry a spare pen and spare needles in case they get lost or stop working. ✗ Never re-use needles. If you do you might not get your dose (underdosing) or get too much (overdosing) as the needle could block.
Need help?
60
Read this first
Learn to inject
How to read the dose window Even numbers are shown in line with the dose pointer:
Put the pen cap back on.
20
60
100
140
180
220
260
100 260
180
220
140 20
60
100
140
260
180
220
100
140
20
60
180 02
06
001
041
081
022
260
062
If no insulin appears:
Pull off the inner needle cap and throw away.
20 units selected Odd numbers are shown as a line between even numbers:
Keep the injection button held in and when you see "0" in the dose window, slowly count to 10.
21 units selected
10 secs
180
220
260
20
60
100
140
After holding and slowly counting to 10, release the injection button. Then remove the needle from your skin.
Trurapi 100 units/ml solution for injection in pre-filled pen comes as injection containing 100iu. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.
The active substance in Trurapi 100 units/ml solution for injection in pre-filled pen is insulin aspart.
Medicines with the same active substance, strength and form include: Fiasp 100 units/mL Penfill solution for injection in cartridge, Fiasp 100 units/mL solution for injection in vial, Trurapi 100 units/ml solution for injection in cartridge. In total there are 4 equivalent products. They are interchangeable only if your prescriber or pharmacist says so.
This leaflet reproduces the patient information leaflet approved for Trurapi 100 units/ml solution for injection in pre-filled pen, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.
Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.
The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.
Trurapi is indicated for the treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above.
Posology
The potency of insulin analogues, including insulin aspart, is expressed in units, whereas the potency of human insulin is expressed in international units.
Trurapi dosing is individual and determined in accordance with the needs of the patient. It should normally be used in combination with intermediate-acting or long-acting insulin.
Blood glucose monitoring and insulin dose adjustments are recommended to achieve optimal glycaemic control.
The individual insulin requirement in adults and children is usually between 0.5 and 1.0 unit/kg/day. In a basal-bolus treatment regimen 50-70% of this requirement may be provided by Trurapi and the remainder by intermediate-acting or long-acting insulin.
Adjustment of dose may be necessary if patients undertake increased physical activity, change their usual diet or during concomitant illness.
Transfer from other insulin medicinal products
When transferring from other insulin medicinal products, adjustment of the Trurapi dose and the dose of the basal insulin may be necessary. Trurapi has a faster onset and a shorter duration of action than soluble human insulin. When injected subcutaneously into the abdominal wall, the onset of action will occur within 10 - 20 minutes of injection. The maximum effect is exerted between 1 and 3 hours after the injection. The duration of action is 3 - 5 hours.
Close glucose monitoring is recommended during the transfer and in the initial weeks thereafter (see section 4.4).
Special populations
Elderly (≥ 65 years old)
Trurapi can be used in elderly patients.
In elderly patients, glucose monitoring should be intensified and the insulin aspart dose adjusted on an individual basis.
Renal impairment
Renal impairment may reduce the patient's insulin requirements.
In patients with renal impairment, glucose monitoring should be intensified and the insulin aspart dose adjusted on an individual basis.
Hepatic impairment
Hepatic impairment may reduce the patient's insulin requirements.
In patients with hepatic impairment, glucose monitoring should be intensified and the insulin aspart dose adjusted on an individual basis.
Paediatric population
Trurapi can be used in adolescents and children aged 1 year and above in preference to soluble human insulin when a rapid onset of action might be beneficial, for example, in the timing of the injections in relation to meals (see sections 5.1 and 5.2).
The safety and efficacy of Trurapi in children below 1 year of age have not been established.
No data are available.
Method of administration
Insulin aspart is a rapid-acting insulin analogue.
Trurapi is administered subcutaneously by injection in the upper arms, thighs, buttocks or abdomen. Injection sites should always be rotated within the same region in order to reduce the risk of lipodystrophy and cutaneous amyloidosis (see section 4.4 and 4.8). Subcutaneous injection in the abdominal wall ensures a faster absorption than other injection sites. Compared to soluble human insulin the faster onset of action of insulin aspart is maintained regardless of the injection site. The duration of action will vary according to the dose, injection site, blood flow, temperature and level of physical activity.
Due to the faster onset of action, insulin aspart should generally be given immediately before a meal. When necessary insulin aspart can be given soon after a meal.
Trurapi 100 units/ml in pre-filled pen is only suitable for subcutaneous injections. If administration by syringe, intravenous injection or infusion pump is necessary, a vial should be used. Other insulin aspart medicinal products offering such an option should be used. Trurapi in pre‑filled pen delivers 1-80 units in increments of 1 unit.
Patients must visually verify the dialled units on the dose counter of the pen. Therefore, the requirement for patients to self-inject is that they can read the dose counter on the pen. Patients who are blind or have poor vision must be instructed to always get help/assistance from another person who has good vision and is trained in using the insulin device.
For detailed user instructions, please refer to the package leaflet.
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Traceability
In order to improve the traceability of biological medicinal products, the name and the batch number of the administered medicinal product should be clearly recorded.
Injection technique
Patients must be instructed to perform continuous rotation of the injection site to reduce the risk of developing lipodystrophy and cutaneous amyloidosis. There is a potential risk of delayed insulin absorption and worsened glycaemic control following insulin injections at sites with these reactions. A sudden change in the injection site to an unaffected area has been reported to result in hypoglycaemia. Blood glucose monitoring is recommended after the change in the injection site, and dose adjustment of antidiabetic medicinal products may be considered.
Hyperglycaemia
Inadequate dosing or discontinuation of treatment, especially in type 1 diabetes, may lead to hyperglycaemia and diabetic ketoacidosis. Usually the first symptoms of hyperglycaemia develop gradually over a period of hours or days. They include thirst, increased frequency of urination, nausea, vomiting, drowsiness, flushed dry skin, dry mouth, loss of appetite as well as acetone odour of breath. In type 1 diabetes, untreated hyperglycaemic events eventually lead to diabetic ketoacidosis, which is potentially lethal.
Hypoglycaemia
Omission of a meal or unplanned, strenuous physical exercise may lead to hypoglycaemia.
Especially in children, care should be taken to match insulin doses (especially in basal-bolus regimens) with food intake, physical activities and current blood glucose level in order to minimise the risk of hypoglycaemia.
Hypoglycaemia may occur if the insulin dose is too high in relation to the insulin requirement. In case of hypoglycaemia or if hypoglycaemia is suspected insulin aspart must not be injected. After stabilisation of patient's blood glucose adjustment of the dose should be considered (see sections 4.8 and 4.9).
Patients whose blood glucose control is greatly improved, e.g. by intensified insulin therapy, may experience a change in their usual warning symptoms of hypoglycaemia, and should be advised accordingly. Usual warning symptoms may disappear in patients with longstanding diabetes.
A consequence of the pharmacodynamics of rapid‑acting insulin analogues is that if hypoglycaemia occurs, it may occur earlier after an injection when compared with soluble human insulin.
Since insulin aspart should be administered in immediate relation to a meal, the rapid onset of action should be considered in patients with concomitant diseases or treatment where a delayed absorption of food might be expected.
Concomitant illness, especially infections and feverish conditions, usually increases the patient's insulin requirements. Concomitant diseases in the kidney, liver or affecting the adrenal, pituitary or thyroid gland can require changes in the insulin dose.
When patients are transferred between different types of insulin medicinal products, the early warning symptoms of hypoglycaemia may change or become less pronounced than those experienced with their previous insulin.
Transfer from other insulin medicinal products
Transferring a patient to another type or brand of insulin should be done under strict medical supervision. Changes in strength, brand (manufacturer), type, origin (animal, human insulin or human insulin analogue) and/or method of manufacture (recombinant DNA versus animal source insulin) may result in the need for a change in dose. Patients transferred to Trurapi from another type of insulin may require an increased number of daily injections or a change in dose from that used with their usual insulin medicinal products. If an adjustment is needed, it may occur with the first dose or during the first few weeks or months.
Injection site reactions
As with any insulin therapy, injection site reactions may occur and include pain, redness, hives, inflammation, bruising, swelling and itching. Continuous rotation of the injection site within a given area reduces the risk of developing these reactions. Reactions usually resolve in a few days to a few weeks. On rare occasions, injection site reactions may require discontinuation of insulin aspart.
Combination of insulin aspart with pioglitazone
Cases of cardiac failure have been reported when pioglitazone was used in combination with insulin, especially in patients with risk factors for development of cardiac heart failure. This should be kept in mind if treatment with the combination of pioglitazone and insulin aspart is considered. If the combination is used, patients should be observed for signs and symptoms of heart failure, weight gain and oedema. Pioglitazone should be discontinued if any deterioration in cardiac symptoms occurs.
Avoidance of accidental mix-ups/medication errors
Patients must be instructed to always check the insulin label before each injection to avoid accidental mix-ups between Trurapi and other insulin medicinal products.
Insulin antibodies
Insulin administration may cause insulin antibodies to form. In rare cases, the presence of such insulin antibodies may necessitate adjustment of the insulin dose in order to correct a tendency to hyper- or hypoglycaemia.
Travel
Before travelling between different time zones, the patient should seek the doctor's advice since this may mean that the patient has to take the insulin and meals at different times.
Sodium
This medicinal product contains less than 1 mmol sodium (23 mg) per dose, that is to sayessentially “sodium‑free”.
A number of medicinal products are known to interact with the glucose metabolism.
The following substances may reduce the patient's insulin requirements:
Oral antidiabetic medicinal products, monoamine oxidase inhibitors (MAOI), beta-blockers, angiotensin converting enzyme (ACE) inhibitors, salicylates, anabolic steroids and sulphonamides.
The following substances may increase the patient's insulin requirements:
Oral contraceptives, thiazides, glucocorticoids, thyroid hormones, sympathomimetics, growth hormone and danazol.
Beta-blockers may mask the symptoms of hypoglycaemia.
Octreotide/lanreotide may either increase or decrease the insulin requirement.
Alcohol may intensify or reduce the hypoglycaemic effect of insulin.
Pregnancy
Trurapi (insulin aspart) can be used in pregnancy. Data from two randomised controlled clinical trials (322 and 27 exposed pregnancies) do not indicate any adverse reaction of insulin aspart on pregnancy or on the health of the fetus/newborn when compared to human insulin (see section 5.1).
Intensified blood glucose control and monitoring of pregnant women with diabetes (type 1 diabetes, type 2 diabetes or gestational diabetes) are recommended throughout pregnancy and when contemplating pregnancy. Insulin requirements usually fall in the first trimester and increase subsequently during the second and third trimester. After delivery, insulin requirements normally return rapidly to pre-pregnancy values.
Breast-feeding
There are no restrictions on treatment with Trurapi during breast-feeding. Insulin treatment of the breast-feeding mother presents no risk to the baby. However, the Trurapi dose may need to be adjusted.
Fertility
Animal reproduction studies have not revealed any differences between insulin aspart and human insulin regarding fertility (see section 5.3).
The patient's ability to concentrate and react may be impaired as a result of hypoglycaemia. This may constitute a risk in situations where these abilities are of special importance (e.g. driving a car or using machines).
Patients should be advised to take precautions to avoid hypoglycaemia while driving, this is particularly important in those who have reduced or absent awareness of the warning signs of hypoglycaemia or have frequent episodes of hypoglycaemia. The advisability of driving should be considered in these circumstances.
Summary of the safety profile
Adverse reactions observed in patients using insulin aspart are mainly due to the pharmacologic effect of insulin.
The most frequently reported adverse reaction during treatment is hypoglycaemia. The frequencies of hypoglycaemia vary with patient population, dose regimens and level of glycaemic control (see section 4.8 Description of selected adverse reactions).
At the beginning of the insulin treatment, refraction anomalies, oedema and injection site reactions (pain, redness, hives, inflammation, bruising, swelling and itching at the injection site) may occur. These reactions are usually of transitory nature. Fast improvement in blood glucose control may be associated with acute painful neuropathy, which is usually reversible. Intensification of insulin therapy with abrupt improvement in glycaemic control may be associated with temporary worsening of diabetic retinopathy, while long-term improved glycaemic control decreases the risk of progression of diabetic retinopathy.
Tabulated list of adverse reactions
Adverse reactions listed below are based on clinical trial data and classified according to System Organ Class. Frequency categories are defined according to the following convention: Very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000); not known (cannot be estimated from the available data).
MedDRA system organ classes
Very common
Uncommon
Rare
Very rare
Not known
Immune system disorders
Urticaria, rash, eruptions
Anaphylactic reactions*
Metabolism and nutrition disorders
Hypoglycaemia*
Nervous system disorders
Peripheral neuropathy (painful neuropathy)
Eye disorders
Refraction disorders, diabetic retinopathy
Skin and subcutaneous tissue disorders
Lipodystrophy*
Cutaneous amyloidosis*
General disorders and administration site conditions
Injection site reactions, oedema
*See section 4.8 Description of selected adverse reactions
Description of selected adverse reactions
Anaphylactic reactions
The occurrence of generalised hypersensitivity reactions (including generalised skin rash, itching, sweating, gastrointestinal upset, angioneurotic oedema, difficulties in breathing, palpitation and reduction in blood pressure) is very rare but can potentially be life threatening.
Hypoglycaemia
The most frequently reported adverse reaction is hypoglycaemia. It may occur if the insulin dose is too high in relation to the insulin requirement. Severe hypoglycaemia may lead to unconsciousness and/or convulsions and may result in temporary or permanent impairment of brain function or even death. The symptoms of hypoglycaemia usually occur suddenly. They may include cold sweats, cool pale skin, fatigue, nervousness or tremor, anxiousness, unusual tiredness or weakness, confusion, difficulty in concentration, drowsiness, excessive hunger, vision changes, headache, nausea and palpitation.
In clinical trials, the frequency of hypoglycaemia varied with patient population, dose regimens and level of glycaemic control. During clinical trials the overall rates of hypoglycaemia did not differ between patients treated with insulin aspart compared to human insulin.
Skin and subcutaneous tissue disorders
Lipodystrophy (including lipohypertrophy, lipoatrophy) and cutaneous amyloidosis may occur at the injection site and delay local insulin absorption. Continuous rotation of the injection site within the given injection area may help to reduce or prevent these reactions (see section 4.4).
Paediatric population
Based on post-marketing sources and clinical trials with insulin aspart, the frequency, type and severity of adverse reactions observed in the paediatric population do not indicate any differences to the broader experience in the general population.
Other special populations
Based on post-marketing sources and clinical trials with insulin aspart, the frequency, type and severity of adverse reactions observed in the elderly patients and in patients with renal or hepatic impairment do not indicate any differences to the broader experience in the general population.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
A specific overdose for insulin cannot be defined, however, hypoglycaemia may develop over sequential stages if too high doses relative to the patient's requirement are administered:
• Mild hypoglycaemic episodes can be treated by oral administration of glucose or sugary products. It is therefore recommended that the diabetic patient always carries sugar‑containing products.
• Severe hypoglycaemic episodes, where the patient has become unconscious, can be treated with glucagon (0.5 to 1 mg) given intramuscularly or subcutaneously by a trained person, or with glucose given intravenously by physicians or other healthcare staff. Glucose must be given intravenously, if the patient does not respond to glucagon within 10 to 15 minutes. Upon regaining consciousness, administration of oral carbohydrates is recommended for the patient in order to prevent a relapse.
Ask anything about Trurapi 100 units/ml solution for injection in pre-filled pen. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.
Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.
We use essential cookies to make the site work. We would also like to set optional cookies to understand how the site is used, so we can improve it. We will not set optional cookies unless you accept. See our cookie policy and privacy policy.